Table.
Baseline Characteristics of Patients With Wall Thinning
| Characteristic | No. (%) | P Value | ||
|---|---|---|---|---|
| All (n = 201) |
Scar Burden | |||
| Extensive (>50%) (n = 164) |
Limited (≤50%) (n = 37)a |
|||
| Age, mean (SD), y | 64.3 (11.9) | 63.7 (11.9) | 67.2 (11.5) | .11 |
| Men | 158 (79) | 130 (79) | 28 (76) | .63 |
| Cardiac risk factors Hypercholesterolemia |
163 (81) | 136 (83) | 27 (73) | .16 |
| Hypertension | 128 (64) | 102 (62) | 26 (70) | .36 |
| Cigarette smoking | 62 (31) | 47 (29) | 15 (41) | .16 |
| Family history of premature CAD | 62 (31) | 48 (29) | 14 (38) | .31 |
| Diabetes | 57 (28) | 47 (29) | 10 (27) | .84 |
| Risk factors present, mean (SD) | 2.3 (1.0) | 2.3 (1.0) | 2.5 (1.0) | .37 |
| Angina | 105 (52) | 85 (52) | 20 (54) | .71 |
| NYHA functional status (classification score), mean (SD) | 2.2 (1.1) | 2.2 (0.9) | 2.3 (0.9) | .79 |
| I | 53 (26) | 44 (27) | 9 (24) | |
| II | 58 (29) | 46 (28) | 12 (32) | |
| III | 80 (40) | 67 (41) | 13 (35) | |
| IV | 10 (5) | 7 (4) | 3 (8) | |
| Cardiac history Prior myocardial infarction |
142 (71) | 119 (73) | 23 (62) | .21 |
| Prior revascularization | 98 (51) | 82 (52) | 16 (46) | .53 |
| Cardiac medications β-Blockers |
144 (72) | 120 (73) | 24 (65) | .31 |
| ACE inhibitors and/or angiotensin receptor blockers | 133 (66) | 110 (67) | 23 (62) | .57 |
| HMG reductase inhibitors | 125 (62) | 105 (64) | 20 (54) | .26 |
| Aspirin | 152 (76) | 126 (77) | 26 (70) | .40 |
| Thienopyridines | 22 (11) | 20 (12) | 2 (5) | .23 |
| Electrocardiographyb Any Q waves |
131 (67) | 108 (68) | 23 (62) | .47 |
| Q waves corresponding to thinned region | 112 (57) | 94 (59) | 18 (49) | .23 |
| Selvester score, mean (SD)c | 6.6 (3.7) | 6.9 (3.6) | 5.2 (3.9) | .009 |
| Coronary angiography, mean (SD)d No. of vessels with CAD (stenosis ≥70%) |
2.03 (0.90) | 2.02 (0.93) | 2.08 (0.80) | .71 |
| Maximum stenosis in artery to thinned region | 84 (30) | 81 (320 | 95 (17) | <.001 |
| Rentrop collateral score to thinned region 0 |
123 (62) | 108 (66) | 15 (41) | .009 |
| 1 | 15 (8) | 11 (7) | 4 (11) | |
| 2 | 25 (13) | 17 (10) | 8 (22) | |
| 3 | 37 (19) | 27 (17) | 10 (27) | |
| Cardiovascular magnetic resonance, mean (SD) Global LV ejection fraction, % |
32.6 (11.5) | 32.1 (11.0) | 34.7 (13.4) | .22 |
| LV surface area thinned, % | 34.2 (15.3) | 34.9 (14.9) | 31.1 (17.0) | .17 |
| Thinned region, mm End-diastolic wall thickness |
4.2 (0.8) | 4.1 (0.9) | 4.5 (0.7) | .02 |
| End-systolic wall thickness | 4.1 (0.9) | 4.1 (0.9) | 4.2 (0.7) | .36 |
| Systolic wall thickening | −0.1 (0.4) | −0.0 (0.3) | −0.2 (0.7) | .06 |
Abbreviations: ACE, angiotensin-converting enzyme; CAD, coronary artery disease; HMG, 3-hydroxy-3-methyl-glutaryl; LV, left ventricular; New York Heart Assocation.
a
Based on 50% or less scarring in the thinned region.
b
Available in 195 patients.
c
Infarct size as determined by electrocardiogram was estimated using the 32-point Selvester QRS scoring system, in which each point is designed to represent approximately 3% of LV mass.
d
Available in 199 patients.